IGX

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Karolinska University Hospital, EudraCT, PD, L-DOPA, Patient, IGX, Doctor of Philosophy, MD, TSX, Clinical trial, Pharmaceutical industry

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.

Key Points: 
  • SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.
  • MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents.

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

Retrieved on: 
Friday, April 5, 2024
Symantec Endpoint Protection, CRL, IGX, Chronic pain, Buprenorphine, TSX, FDA, Food, Pharmaceutical industry

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.

Key Points: 
  • SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.
  • The CRL includes a request for additional Pharmaceutical Quality information.
  • Buprenorphine Buccal Film, which incorporates IntelGenx’s VersaFilm® technology in a novel formulation, is a generic version of Belbuca®, an opioid that is used to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments are inadequate.
  • Approved by the FDA in 2015, Belbuca® is applied to the oral or buccal mucosa every 12 hours and comes in seven strengths ranging from 0.075 mg to 0.9 mg.

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

Retrieved on: 
Thursday, March 14, 2024
Webcast, Conference, TSX, IGX

SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.

Key Points: 
  • SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.
  • An accompanying conference call will be hosted by Dwight Gorham, Chief Executive Officer and Andre Godin, President and Chief Financial Officer to discuss the results and provide a business update.
  • Details of the conference call and webcast are below:
    Fourth Quarter and Full Year 2023 Results Conference Call Details:

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

Retrieved on: 
Monday, March 11, 2024
Acquisition, Loan agreement, TSX, Toronto Stock Exchange, Sale, Exercise, Loan, Multilateral, Bankruptcy, Conversion, IGX, National instrument, Security (finance), Minority, Related, VWAP

Concurrently to entering into the Loan Agreement, the Company has issued 4,000,000 warrants (the “Warrants”) to atai.

Key Points: 
  • Concurrently to entering into the Loan Agreement, the Company has issued 4,000,000 warrants (the “Warrants”) to atai.
  • The Warrants entitle atai to purchase Shares at a price of US$0.17 per Share, for a period of 36 months following their issuance.
  • The shorter period was necessary in order to permit the Company to close the Loan Agreement in a timeframe consistent with usual market practice for transactions of this nature.
  • This press release does not constitute an offer of securities for sale in the United States.

IntelGenx Launches Preferred Share Regulation A Offering

Retrieved on: 
Tuesday, February 20, 2024
TSX, Toronto Stock Exchange, Common stock, Growth, Regulation A, Rest, IGX, Security (finance)

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000.

Key Points: 
  • SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A Preferred Stock”), par value $0.00001 per share, at an offering price of $10.00 per share (the “Offering”), for a maximum Offering amount of $20,000,000.
  • Holders of the Series A Preferred Stock will be entitled to receive cumulative dividends in the amount of $0.20 per share each quarter, or 8% per year.
  • An Offering Statement on Form 1-A, as amended (the “Offering Statement”), relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) and has been qualified.
  • A copy of the Preliminary Offering Circular that forms a part of the Offering Statement is available on the Company’s EDGAR profile at www.sec.gov/edgar .

Lattice Semiconductor Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, February 12, 2024
Engineering, Semiconductor, Technology, Manufacturing, Networks, Internet, Hardware, Nexus, Table, Lattice Semiconductor, Conference, BMW, Meta, GAAP, IGX, Most, FPGA, NVIDIA

Fourth Quarter and Full Year 2023 Highlights:

Key Points: 
  • Fourth Quarter and Full Year 2023 Highlights:
    Full Year Revenue Growth: Revenue for the full year 2023 increased 12% compared to 2022.
  • Over 30 Industry Awards: Lattice received over 30 industry awards during 2023, including the Global Semiconductor Alliance's Most Respected Semiconductor Company for the fourth consecutive year and Best Financially Managed Semiconductor Company.
  • Business Outlook - First Quarter of 2024:
    Revenue for the first quarter of 2024 is expected to be between $130 million and $150 million.
  • Investor Conference Call / Webcast Details:
    Lattice Semiconductor will review the Company's financial results for the fiscal fourth quarter and full year 2023, and business outlook on Monday, February 12 at 5:00 p.m. Eastern Time.

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

Retrieved on: 
Monday, February 5, 2024
IGX, Dog, Animal Health, POC, Animal, TSX, Veterinarian, UPEI, Capsule, Cat, Tablet

The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”), one of North America’s leading veterinary universities.

Key Points: 
  • The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”), one of North America’s leading veterinary universities.
  • The reliable administration of medications to dogs and cats is a concern for many owners and veterinarians.
  • Forced administration of capsules, tablets and liquids may be stressful for both the pet and its owner(s).
  • “We would like to thank the esteemed clinicians and researchers at UPEI, the many pet owners, and of course the cherished dogs and cats that participated in these studies.”

IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

Retrieved on: 
Monday, December 18, 2023
IGX, Partnership, Animal, Animal Health, Covenant, TSX, Veterinarian, Medicine

SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”).

Key Points: 
  • SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”).
  • Under the terms of the development agreement, Covenant Animal Health will fund development and manufacturing of a VetaFilm®-based drug (the “Product”).
  • The license agreement will give Covenant Animal Health exclusive rights to exploit the Product in the field for non-human applications.
  • IntelGenx will manufacture the Product on worldwide basis for clinical development, and the parties anticipate entering into a subsequent commercial supply agreement, pursuant to which IntelGenx will supply the Product to Covenant Animal Health.

IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

Retrieved on: 
Tuesday, December 5, 2023
IGX, Customary international law, Multilateral, Special, Call option, Proxy, TSX, Toronto Stock Exchange, Minority, Exercise, Security (finance)

SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent non-brokered private placement (the “Subsequent atai Subscription”) of 750 units (“US Units”) with atai Life Sciences AG (“atai”) for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units (the “Initial Offering” and together with the Subsequent atai Subscription, the “Offering”), following the Shareholder Approvals (as defined below) obtained at the special meeting held on November 28, 2023 (the “Special Meeting”).

Key Points: 
  • SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent non-brokered private placement (the “Subsequent atai Subscription”) of 750 units (“US Units”) with atai Life Sciences AG (“atai”) for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units (the “Initial Offering” and together with the Subsequent atai Subscription, the “Offering”), following the Shareholder Approvals (as defined below) obtained at the special meeting held on November 28, 2023 (the “Special Meeting”).
  • The US Notes are convertible into shares of common stock of the Company (the “Shares”) at the option of atai at a price of US$0.185 (the “US Conversion Price”) at anytime following their issuance up to and including August 31, 2026, and bear interest at 12% per annum, payable quarterly, in arrears.
  • The US Warrants entitle atai to purchase Shares at a price of US$0.26 per Share until December 4, 2026.
  • As previously disclosed by the Company, atai is an insider of the Company as a result of its beneficial ownership of, or control or direction over, directly or indirectly, greater than 10% of the outstanding Shares.

IntelGenx Announces Changes to its Board of Directors

Retrieved on: 
Monday, December 4, 2023
General counsel, IGX, TSX, Senior

SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023.

Key Points: 
  • SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “Board”) effective December 2, 2023.
  • On December 2, 2023, the Board appointed Sahil Kirpekar, M.D.
  • and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 annual meeting of the Company’s stockholders, or until their respective successors are duly elected and qualified.
  • Dr. Kirpekar has served as atai’s Chief Business Officer since 2022 and Mr. Barrett has served as atai’s Senior Vice President and General Counsel since August 2020.